Clarivate Reports Fourth Quarter and Full Year 2025 Results

Core Insights - Clarivate achieved significant innovation and growth in 2025, advancing its Value Creation Plan and enhancing its business model, resulting in nearly 2% organic ACV growth and improved cash flow [1][2][4] - The company is currently engaged in discussions to sell its Life Sciences & Healthcare business, aiming to focus on Academia & Government and Intellectual Property markets [1][2][4] - Financial outlook for 2026 projects continued momentum with expected organic ACV growth of 2.0% to 3.0% and recurring organic revenue growth of 0.75% to 2.25% [2][4][5] Financial Performance - Total revenues for Q4 2025 were $617.0 million, down from $663.0 million in Q4 2024, with a 1.2% organic revenue decline [1][2] - Net income for Q4 2025 improved to $3.1 million, compared to a net loss of $191.8 million in the prior year [1][2] - For the full year 2025, total revenues were $2,455.2 million, down from $2,556.7 million in 2024, with organic revenues declining by 0.1% [1][2] Revenue Breakdown - Subscription revenues for Q4 2025 were $405.8 million, slightly down from $407.0 million in the prior year, with a 1.0% organic increase [2][4] - Total recurring revenues increased 0.5% organically, while transactional revenues fell to $97.1 million from $144.0 million due to divestitures [2][4] - For the full year 2025, subscription revenues were $1,605.5 million, down from $1,626.8 million in 2024, with organic subscription revenue growth of 0.8% [2][4] Cash Flow and Debt Management - Clarivate generated $628.5 million in operating cash flow and $365.3 million in free cash flow during 2025 [1][2] - The company returned approximately $225 million to shareholders through share repurchases, including 21.2 million shares in Q4 2025 [1][2] - As of December 31, 2025, cash and cash equivalents were $329.2 million, with total debt outstanding at $4,469.9 million, a decrease of $101.2 million from the previous year [2][4] Strategic Review and Future Outlook - The company is pursuing a sale of its Life Sciences & Healthcare business to strengthen its balance sheet and focus on core markets [1][2] - The 2026 outlook anticipates revenues between $2.30 billion and $2.42 billion, with adjusted EBITDA projected at $980 million to $1.04 billion [2][4][5] - The company aims for a disciplined execution strategy, continued organic growth, and thoughtful capital allocation moving forward [1][2]